This database contains 222 studies, archived under the term: "cognition disorders"
Click here to filter this large number of results.
Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert’s opinion
Calabro, Rocco Salvatore,
Gervasi, Giuseppe,
Baglieri, Annalisa,
Furnari, Anna,
Marino, Silvia,
Bramanti, Placido
Background: Leukoraraiosis is worldwide considered as a part of the normal aging process, although it is strongly associated with dementia and other disabilities. The pathogenesis of leukoaraiosis still has not been thoroughly acknowledged, even though chronic ischemia with consequent arteriolosclerosis probably due to endothelial dysfunction has been suggested. Treatment focuses on prevention of lesion formation […]
Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON)
Hooghiemstra, Astrid M.,
Eggermont, Laura H.P.,
Scheltens, Philip,
van der Flier, Wiesje M.,
Bakker, Jet,
de Greef, Mathieu H. G.,
Koppe, Peter A.,
Scherder, Erik J.A.
Background: Although the development of early-onset dementia is a radical and invalidating experience for both patient and family there are hardly any non-pharmacological studies that focus on this group of patients. One type of a non-pharmacological intervention that appears to have a beneficial effect on cognition in older persons without dementia and older persons at […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
A 1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline
Lam, Linda C. W.,
Chau, Rachel C. M.,
Wong, Billy M. L.,
Fung, Ada W. T.,
Tam, Cindy W. C.,
Leung, Grace T. Y.,
Kwok, Timothy C. Y.,
Leung, Tony Y. S.,
Ng, Sammy P.,
Chan, Wai M.
Objectives: To compare the effectiveness of Chinese-style mind-body exercise (24 forms simplified Tai Chi) versus stretching and toning exercise in the maintenance of cognitive abilities in Chinese elders at risk of cognitive decline.; Design: A 1-year single-blind cluster randomized controlled trial.; Settings: Community centers and residential homes for elders in Hong Kong.; Participants: A total […]
Dairy consumption and working memory performance in overweight and obese adults
All individuals will experience some degree of cognitive impairment in their later years. Diet is one readily modifiable factor that may influence cognitive function and psychological well-being. Very little research has considered the potential role of dairy foods in modulating cognitive and psychological functions. The objective of this study was to determine the effect of […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease
Witt, Karsten,
Daniels, Christine,
Krack, Paul,
Volkmann, Jens,
Pinsker, Markus O.,
Kloss, Manja,
Tronnier, Volker,
Schnitzler, Alfons,
Wojtecki, Lars,
Bötzel, Kai,
Danek, Adrian,
Hilker, Rüdiger,
Sturm, Volker,
Kupsch, Andreas,
Karner, Elfriede,
Deuschl, Günther
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in Parkinson’s disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline […]
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD
Egan, Michael,
Yaari, Roy,
Liu, Lian,
Ryan, Michael,
Peng, Yahong,
Lines, Christopher,
Michelson, David
We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients. Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo. Pharmacokinetic and PET data suggested that MK-0249 5-mg daily would achieve approximately 85% […]